Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration

References

• Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022 Jan 29;399(10323):473–86. doi: 10.1016/S0140-6736(21)01730-X
   PubMed Web of Science ®Google Scholar
• Velligan DI, Rao S. The epidemiology and Global Burden of schizophrenia. J Clin Psychiatry. 2023 Jan 18;84(1):MS21078COM5. doi: 10.4088/JCP.MS21078COM5
   PubMed Web of Science ®Google Scholar
• Marder SR, Cannon TD, Ropper AH. Schizophrenia. N Engl J Med. 2019 Oct 31;381(18):1753–1761. doi: 10.1056/NEJMra1808803
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013 Oct;150(1):31–35. doi: 10.1016/j.schres.2013.05.004
   PubMed Web of Science ®Google Scholar
• Jaeschke K, Hanna F, Ali S, et al. Global estimates of service coverage for severe mental disorders: findings from the WHO Mental Health atlas 2017. Global Mental Health (Cambridge, England). 2021;8:e27. doi: 10.1017/gmh.2021.19
   Web of Science ®Google Scholar
• Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010 Nov;24(4 Suppl):81–90. doi: 10.1177/1359786810385490
   PubMed Web of Science ®Google Scholar
• De Berardis D, De Filippis S, Masi G, et al. A neurodevelopment approach for a transitional model of early onset schizophrenia. Brain Sci. 2021 Feb 23;11(2):275. doi: 10.3390/brainsci11020275
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Bellomo A, Ricci F, et al. New pharmacological targets for the treatment of schizophrenia: a literature review. Curr Top Med Chem. 2021 Oct 25;21(16):1500–16. doi: 10.2174/1568026621666210701103147
   PubMed Web of Science ®Google Scholar
• Ferri F, Costantini M, Salone A, et al. Binding action and emotion in first-episode schizophrenia. Psychopathology. 2014;47(6):394–407.
   PubMed Web of Science ®Google Scholar
• Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul 24;511(7510):421–427. 10.1038/nature13595
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an Overview. JAMA Psychiatry. 2020 Feb 1;77(2):201–10. doi: 10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• Fišar Z. Biological hypotheses, risk factors, and biomarkers of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. Prog Neuro Psychopharmacol Biol Psychiatry. 2023 Jan 10;120:110626. doi: 10.1016/j.pnpbp.2022.110626
   PubMed Web of Science ®Google Scholar
• Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules (Basel, Switzerland). 2018 Aug 20;23(8):2087. doi: 10.3390/molecules23082087
   PubMed Web of Science ®Google Scholar
• Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Advances Pharmacol (San DiegoCalif). 2016;76:351–82.
   PubMedGoogle Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic Evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675–684. doi: 10.1001/jamapsychiatry.2017.0624
   PubMed Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020 Sep 1;177(9):868–872. doi: 10.1176/appi.ajp.2020.177901
   PubMed Web of Science ®Google Scholar
• Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia. Neuropsychopharmacol Rep. 2021 Sep:41(3):266–324. doi:10.1002/npr2.12193
   PubMed Web of Science ®Google Scholar
• Orzelska-Górka J, Mikulska J, Wiszniewska A, et al. New atypical antipsychotics in the treatment of schizophrenia and depression. Int J Mol Sci. 2022 Sep 13;23(18):10624. doi: 10.3390/ijms231810624
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193–206. doi: 10.1517/17425255.2013.759211
   PubMed Web of Science ®Google Scholar
• Prommer EA. Aripiprazole. Am J Hospice & Palliative Care. 2017 Mar;34(2):180–85. doi: 10.1177/1049909115612800
   PubMed Web of Science ®Google Scholar
• Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015 Dec;76(12):e1574–82. doi: 10.4088/JCP.15m09997
   PubMed Web of Science ®Google Scholar
• Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem. 2016;16(29):3385–403. doi: 10.2174/1568026616666160608084834
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64(1):393–406. doi: 10.1146/annurev-med-050911-161504
   PubMedGoogle Scholar
• He S, Yu WJ, Wang X, et al. Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids. General Psychiatry. 2020;33(4):e100206.
   PubMed Web of Science ®Google Scholar
• Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017 Oct 18;18(10):2174. doi: 10.3390/ijms18102174
   PubMed Web of Science ®Google Scholar
• Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013 Nov;39(6):1296–1306. doi: 10.1093/schbul/sbs130
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018 Oct 17;44(6):1195–1203. doi: 10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015 Jun;114(1):169–79. doi: 10.1093/bmb/ldv017
   PubMed Web of Science ®Google Scholar
• Cho DI, Zheng M, Kim KM. Current perspectives on the selective regulation of dopamine D₂ and D₃ receptors. Arch Pharm Res. 2010 Oct;33(10):1521–38. doi: 10.1007/s12272-010-1005-8
   PubMed Web of Science ®Google Scholar
• Gross G, Wicke K, Drescher KU. Dopamine D₃ receptor antagonism–still a therapeutic option for the treatment of schizophrenia. Naunyn-Schmiedeberg’s Arch Pharmacol. 2013 Feb;386(2):155–66. doi: 10.1007/s00210-012-0806-3
   Google Scholar
• Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology. 2005 May;179(3):567–575. doi: 10.1007/s00213-004-2096-z
   PubMed Web of Science ®Google Scholar
• Pourhamzeh M, Moravej FG, Arabi M, et al. The roles of serotonin in neuropsychiatric disorders. Cell Mol Neurobiol. 2022 Aug;42(6):1671–1692. doi: 10.1007/s10571-021-01064-9
   PubMed Web of Science ®Google Scholar
• Saha S, González-Maeso J. The crosstalk between 5-HT(2A)R and mGlur2 in schizophrenia. Neuropharmacology. 2023 Jun 1;230:109489. doi: 10.1016/j.neuropharm.2023.109489
   PubMed Web of Science ®Google Scholar
• Omura GA. Phase 1 dose-finding trials and fibonacci. Clin Cancer Res. 2006 Jan 1;12(1):321. doi: 10.1158/1078-0432.CCR-05-1762
   PubMed Web of Science ®Google Scholar
• Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–422. doi: 10.1517/17425255.2016.1154043
   PubMed Web of Science ®Google Scholar
• Hiemke C, Pfuhlmann B. Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol. 2012;212:241–65.
   PubMedGoogle Scholar
• Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013 Dec;27(12):1021–1048. doi: 10.1007/s40263-013-0114-6
   PubMed Web of Science ®Google Scholar
• Buzea CA, Dima L, Correll CU, et al. Drug-drug interactions involving antipsychotics and antihypertensives. Expert opinion on drug metabolism & toxicology. 2022 Apr;18(4):285–98. doi: 10.1080/17425255.2022.2086121
   Google Scholar
• Periclou A, Phillips L, Ghahramani P, et al. Population pharmacokinetics of cariprazine and its major metabolites. Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):53–69. doi: 10.1007/s13318-020-00650-4
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, McDonald WM, Widge AS, et al. Neuroimaging biomarkers in schizophrenia. Am J Psychiatry. 2021 Jun;178(6):509–521. doi: 10.1176/appi.ajp.2020.20030340
   PubMed Web of Science ®Google Scholar